BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1751 related articles for article (PubMed ID: 19775421)

  • 1. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
    Onuigbo MA
    Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal failure and concurrent RAAS blockade in older CKD patients with renal artery stenosis: an extended Mayo Clinic prospective 63-month experience.
    Onuigbo MA; Onuigbo NT
    Ren Fail; 2008; 30(4):363-71. PubMed ID: 18569908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study.
    Onuigbo MA; Onuigbo NT
    Ren Fail; 2008; 30(1):67-72. PubMed ID: 18197546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors.
    Onuigbo MA; Onuigbo NT
    Ren Fail; 2008; 30(1):73-80. PubMed ID: 18197547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial.
    Kiski D; Stepper W; Brand E; Breithardt G; Reinecke H
    Nephrol Dial Transplant; 2010 Mar; 25(3):759-64. PubMed ID: 19903660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET--a call for more circumspection.
    Onuigbo MA
    QJM; 2009 Mar; 102(3):155-67. PubMed ID: 19098074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
    Turgut F; Balogun RA; Abdel-Rahman EM
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acute renal failure due to RAAS-inhibitors combined with dehydration].
    Scherpbier ND; de Grauw WJ; Wetzels JF; Vervoort GM
    Ned Tijdschr Geneeskd; 2010; 154():A1548. PubMed ID: 20699027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution.
    Onuigbo MA
    Nephron Clin Pract; 2009; 113(2):c63-9, discussion c70. PubMed ID: 19602900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Untoward effects of chronic dual renin-angiotensin system blockade: influence of previous chronic renal failure.
    Robles NR; Cancho B; Barroso S; Martín MV; Sánchez Casado E
    Int J Clin Pract; 2006 Sep; 60(9):1035-9. PubMed ID: 16939543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience.
    Onuigbo MA; Onuigbo NT
    Med Sci Monit; 2005 Oct; 11(10):CR462-9. PubMed ID: 16192897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
    Jennings DL; Taber DJ
    Ann Pharmacother; 2008 Jan; 42(1):116-20. PubMed ID: 18094340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.